Ondine Biomedical reports 70% revenue surge in 2024

Published 15/05/2025, 07:10
Ondine Biomedical reports 70% revenue surge in 2024

VANCOUVER - Ondine Biomedical Inc. (AIM:OBI), known for its light-activated antimicrobial technologies, has disclosed a significant revenue increase in its full year results for 2024. The company announced a 70% surge in revenue to $2.0 million, up from $1.2 million the previous year, attributing the growth to an 81% rise in hospital deployments and increased per-hospital revenue.

Despite a 40% cut in sales and marketing expenses, the Vancouver-based firm expanded its commercial reach, particularly in the UK, where its Steriwave® product became the first light-activated antimicrobial listed on the NHS Supply Chain. This listing is expected to facilitate access to hospitals across England and Wales.

Ondine Biomedical also entered a strategic distribution partnership with Mölnlycke Health Care, aiming to extend Steriwave’s international presence into key markets such as the UK, EU, and Middle East. Mölnlycke is a globally recognized MedTech company whose products are utilized in over 100 countries.

Financially, the company saw its gross margin improve to 64% from the previous year’s 58%, a result of operational efficiencies and the launch of an enhanced Steriwave nasal illuminator. The new illuminator is designed for high-volume manufacturing and is expected to contribute to improved margins.

In terms of funding, Ondine successfully raised $21.7 million net cash in 2024 and secured an additional $5.7 million from a leading US healthcare entity post-financial year-end. These funds are earmarked for initiating the Phase 3 LANTERN clinical trial and supporting further commercial expansion.

The company’s pivotal US Phase 3 LANTERN clinical trial commenced in December 2024, with patient recruitment actively progressing at 10 of the 14 planned HCA Healthcare (NYSE:HCA) hospitals. However, the company anticipates a delay in last patient recruitment by approximately one quarter.

Additionally, Ondine has collaborated with the Royal Columbian Hospital Foundation on a clinical development program to speed up entry into the ICU market. A four-month ICU pilot trial began recruiting patients in March 2025.

Despite the revenue growth, the company reported an operating loss of $19.4 million, up from $14.8 million in 2023, reflecting increased investment in clinical trials, FDA audit readiness, and operational infrastructure to support future growth.

Dr. Nicolas Loebel, President and CTO, will provide further details on the results in a live presentation today, with a recording and related slides to be made available on the company’s website. This article is based on a press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.